Molecular diagnostics company Qiagen will invest $10 million to build out manufacturing capabilities at its Germantown, MD, campus by early 2015, focusing on products for women's health and infectious disease.
Qiagen snatched up a biomarker from an Austrian research group that will aid in the development of a test designed to better diagnose rare blood disorders.
Qiagen has started marketing a next-generation tuberculosis blood test in China, four months after winning regulatory approval there in what will be a key market for the company in the months ahead.
Dutch molecular diagnostics conglomerate Qiagen launched its new human papillomavirus test in India for women in areas with limited healthcare infrastructure. The company is touting the careHPV test as the first designed specifically with this patient group in mind.
Qiagen has rolled out a new test for high-risk human papillomavirus in India designed to screen women in areas with limited healthcare infrastructure.
Qiagen and Exosome Diagnostics will partner to develop innovative, noninvasive molecular in vitro diagnostics to detect lung cancer and other malignancies.
Qiagen won Chinese regulatory approval for a next-generation tuberculosis test and expects a commercial rollout there in the early part of 2014.
With the success of Erbitux and its patient-steering companion diagnostic fresh in mind, Qiagen and Eli Lilly have struck up their third partnership, reuniting to match genomic knowhow with drug development expertise.
Biotech Clovis Oncology is tapping Qiagen's diagnostic expertise as it develops an EGFR-targeting lung cancer treatment, tasking the German company with creating a companion test that can identify patients for clinical trials and, eventually, be sold alongside the drug.
Qiagen plans to move ahead with a $100 million share repurchase program in the wake of improved revenue and sales in the 2013 second quarter on nearly all fronts.